Suven Share Price (SUVEN)

Suven Life Sciences Limited (erstwhile Suven Pharmaceuticals), established in 1989, is in the business of Contract Research and Manufacturing Services (CRAMS), providing process research and rapid response pilots scale 16 manufacture, custom synthesis, process R&D, and contract manufacturing of intermediates, APIs and formulations. It has two international wholly owned subsidiaries and one Indian wholly owned subsidiary. With the aim of expanding its drug discovery portfolio, a remarkable growth of 71% in total sales and a 325% growth in profit after tax (PAT) was registered during 2000-01. In addition, the company also acquired a pilot plant and got its recertification of ISO 9002 during the same year. In 2013-14, Suven granted an exclusive license to Taro Pharmaceuticals to market its product Head Lice Lotion in the US, Canada and Mexico, estimated at US$35million. During FY2014-15, one of its lead clinical candidates SUVN 502 has successfully completed the Phase 1b clinical trial, leading way for the entry into Proof of Concept (PoC) Phase 2a study. Thesaid year also saw the Company issuing and alloting 10, 453, 690 equity shares of Re 1/ each at a premium of Rs190.32 per share by way of QIP issue. In 2018-19, a Scheme of Arrangement for Demerger was initiated between Suven Life Sciences and Suven Pharmaceuticals Limited, resulting in a mirror shareholding of Suven Life Sciences in Suven Pharmaceuticals Limited. Consequently, Suven Pharmaceuticals Ltd., India and Suven Pharma Inc., USA became subsidiary companies of the group. As of 31st March 2019, investments were made to Suven Neurosciences Inc., a wholly owned subsidiary, amounting to Rs. 13, 636 lakh and no investments were made into newly formed Suven Pharma Inc., USA.

Revenue: ₹1.47Cr as on March 2025 (Q4 FY25)
Net Profit: ₹-43.94Cr as on March 2025 (Q4 FY25)
Listing date: 23 Oct, 2003
Chairperson Name: Venkateswarlu Jasti